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Stress is a risk factor for a number of diseases and is an important predictor of health in general. Herbal
medicines have been used as adaptogens to regulate and improve the stress response and there is
evidence to support the use of herbal medicines for this purpose. We conducted an open-label
longitudinal study on the natural health product, OCTA , a compound mixture of eight herbs, to
determine its effects on perceptions of stress. Eighteen participants were enrolled in the study and were
followed over a period of 3 months. Primary endpoints included scores from four validated
questionnaires (SF-36v2, PSS, STAI and BDI-II), serum DHEA, ALT, AST and creatinine all measured
at 12 weeks. Seventeen patients completed the study. Except for the physical summary score of the SF36
questionnaire, all the subjective scores indicated a highly significant (P < 0.0001) improvement in the
participants’ ability to cope with stress. No adverse effects were reported and there was no evidence of
damage to the liver or kidney based on serum markers. Initial evidence for this polyherbal compound
supports its potential as an effective ‘adaptogenic’ aid in dealing with stress. Further research using a
randomized controlled design is necessary to confirm the findings from this pilot study.
Keywords: adaptogen – CAM – clinical trial – complementary and alternative medicine –
herbal medicine – stress
Introduction
Stress is an extremely broad term that serves to define a wide
variety of phenomena that humans are exposed to throughout
their lives. The facets of stress are essentially limitless;
however, broad categories include physical exertion, emo-
tional upset, persistent psychological pressure, existential
crisis and the residual effects of emotional trauma. The 1993
World Labour Report by the UN’s International Labour
Organization claimed that stress had become one of the most
serious health issues of the 20th century (1). Stress and its
resultant comorbidity are responsible for a large proportion of
disability worldwide. It has consistently been shown that
individuals experiencing stress have impaired physical and
mental functioning; more workdays lost, impairment at work
and increased use of healthcare services. The disability caused
by stress is just as great as the disability caused by workplace
accidents or other common medical conditions such as hyper-
tension, diabetes and arthritis (2). The World Health Organ-
ization (WHO) Global Burden of Disease Survey estimates
that mental disease, including stress-related disorders, will be
the second leading cause of disability by the year 2020 (3).
Since the characterization of the generalized adaptation
syndrome (GAS) by Hans Selye, the issue of stress has come
tobeviewedasa riskfactorinboth the etiology and progression
of a wide variety of diseases. Chronic and post-traumatic stress
has been implicated in cardiovascular disease (4–6), gastroin-
testinal ulceration (7), inflammatory bowel disease (7), depres-
sion (8,9), anxiety (9), fibromyalgia (10), autoimmune disease
(11) and schizophrenia (12). In addition, chronic stress clearly
demonstrates the ability to negatively impact immune system
function and can predispose a person toward infection (13–15).
Evidence also demonstrates that stress very early in life, i.e.
within the first few years of childhood, may be an etiological
agent for the development of type 1 diabetes (16) and also
potentially in the development and severity of asthma (17).
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and the body is able to return to normal parasympathetic
homeostasis. Stress becomes pathologic, however, when it is
chronic or when the body acquires an inherent tendency
towards activation of the sympathetic nervous system (15,18).
Current therapies for dealing with ‘stress’ are extensive but
perhaps not ideally targeted in most cases. Pharmacological
approaches are principally focused on the treatment of
depression and the manifestations of both acute and chronic
anxiety disorders (19).
A potentially beneficial use of herbal medicine involves the
use of herbs as ‘adaptogens’ in order to prevent stress-induced
morbidity. From an herbalist’s perspective, the therapeutic
intent of an adaptogen is to promote an optimal physiological
response to both internal and external stresses. Essentially the
adaptogen supports the body’s ability to ‘adapt’ ideally to its
environment. These herbs are believed to have a bimodal
function of action either by providing a stimulant effect or a
sedative effect depending on the needs of the individual in
a particular situation. Common examples of adaptogens
include Asian ginseng (L. Panax ginseng), Siberian ginseng
(Eleutherococcus senticosus), Ashwagandha root (Withania
somnifera) and rhodiola (L. Rhodiola rosea) (20). Herbs are
not the only potential adaptogens as other agents like vitamins
and even amino acids have also exhibited this kind of
activity (21).
In the 1950s, Russian scientists set out specific criteria that an
herb had to incorporate in order to be considered an adaptogen.
The criteria were that the herb must (i) only cause minimal
disorders in physiological function; (ii) must increase resistance
toexternalandinternalstressesthroughawiderangeofphysical,
chemical, and biochemical factors; and (iii) must have a
normalizing effect, improving all types of conditions while
aggravating none (22,23). Specificexamples ofhow adaptogens
have beentaken toimprove health include theirusage to: reduce
fatigue, regain or improve athletic performance, regain or
improve mental acuity, increase appetite, relieve insomnia,
improve mood and increase resistance against infection
(15,23,24). For an intriguing discussion on how adaptogens
may impact health, the reader is referred to a series of articles
published by Olalde Rangel et al. in 2005 (25–28).
Relatively little clinical research has been conducted on
the use of herbal adaptogens for stress, and still less on
combinations of herbal medications. In this paper, we report
on the results of an open-label uncontrolled longitudinal trial on
the use of a proprietary herbal compound mixture, OCTA ,o n
subjective parameters of stress as well as objective measures.
Methods
Design and Participants
We conducted an open-label and uncontrolled clinical trial
to evaluate the impact of OCTA  on known parameters of
stress. We enrolled 18 participants between the ages of 21 and
58 years old (mean 39.5 years) with a relatively even sex
distribution (8 males and 10 females). Self-reported stress
levels at enrollment were initially evaluated using the
Perceived Stress Level test. For inclusion, participants had
to have experienced one or more illnesses potentially related
to stress including anxiety, arthritis, chronic pain, depression,
diabetes, eczema, headaches, heart attacks, heart disease,
impotence, decreased libido, high blood pressure or peptic
ulceration. Participants were excluded from enrollment if they
were under 18 years old, were pregnant, planning to become
pregnant or were taking any of the following medications:
glucocorticoids, androgens, birth control pills, anti-seizure
drugs, diuretics, barbiturates, sedatives or anxiolytics.
Participants were recruited through newspaper and radio
advertisements run for a period of 2 weeks. The message
conveyed was that we were looking for individuals adversely
affected by stress. As compensation for their involvement,
participants were offered a $50 gift certificate and a free
nutritional consultation at the completion of the study.
Participants were not required to be actively seeking treatment.
Interested participants contacted the study coordinator (R.S.)
and attended an information session that detailed the protocol.
The timing, severity and history of the participants’ complaints
were not assessed. Only subjective questionnaires were used to
measure changes in outcome but not with respect to the
particular complaint or chief concern of the participants but
rather to measure overall changes in quality of life.
We conducted a physical examination to rule out underlying
pathology. Participants were advised to exclude any supple-
ments designed to mitigate the effects of stress including any
natural health products that weren’t taken for general health.
The only supplements consumed by any of the participants
included multivitamins, flax oil and vitamin C. The partici-
pants were advised to continue their lifestyle, maintain their
normal diet and vitamin consumption and change nothing
except for the addition of the OCTA . Participants were
followed over a 3 month period and asked to come in for
assessment at predefined time points including at baseline,
2 weeks, 4 weeks, 8 weeks, and 12 weeks. At each time point,
the participants were administered self-reported standardized
questionnaires, had their blood pressure monitored and
had blood samples taken for specific laboratory tests. To be
enrolled, participants had to sign an informed consent form and
be assessed by a physician. Participants were permitted to ask
questions at any time during the study.
Intervention
Participants were provided with the proprietary herbal
compound OCTA , an aqueous-based liquid herbal
preparation consisting of eight herbs as follows: W. somnifera,
Lagerstroemia speciosa, Bacopa monniera, Zizyphus jujuba,
Morinda citrifolia, Punica granatum, Shisandrae chinensis
and Lycium barbarum (listed in descending order according to
respective concentrations). Participants were instructed to
consume two tablespoons (30 ml) of the herbal compound per
day each morning for a total period of 3 months.
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demonstrated consistent concentrations of the herbal extracts.
The two main ingredients are derived from standardized
extracts (W. somnifera: 2.5% with anolides; and L. speciosa:
1% corosolic acid). OCTA  has been under review by Health
Canada’s Natural Health Products Directorate (NHPD) since
2004 but due to a backlog of requests has yet to be processed.
The manufacturer adheres to GMP standards and is certified by
Australia’s Therapeutics Goods Administration (TGA), the
Department of Health of the State of New Jersey, and has
received an ‘A’ rating from the National Nutritional Foods
Association (NNFA).
Outcome Measures
Study endpoints assessed and analyzed for each of the
participants consisted of both objective and subjective mea-
sures. Aside from serum dehydroepiandrosterone (DHEA), the
objective measures were not primary outcomes but were
included in order to assess for patient safety and the potential
for liver or kidney toxicity. Secondary objective measures
included blood pressure, cholesterol levels, aspartate transami-
nase (AST), alanine transaminase (ALT) and urinary creati-
nine. Primary outcome measures consisted of subjective scores
from four self-reported questionnaires including the perceived
stress scale, the state/trait anxiety scale, the beck depression
index and the SF36 Health Survey (Version 2) questionnaire.
These questionnaires, described briefly below, were chosen
because they have been validated and are widely accepted
amongst healthcare professionals.
The SF36 Health Survey (SF-36v2) questionnaire is one
of the most extensively used and validated quality of life
measures. It is a self-administered, 36-item questionnaire
that measures health-related quality of life in 8 domains that
consist of both physical and mental-related issues. The
physical and mental scores can be summarily added in order
to obtain overall summaries of each of these two distinct
areas. The reliability of the test is well documented with a
Cronbach’s alpha value greater than 0.85 (29).
The Perceived Stress Scale (PSS) is the most widely used
psychological instrument for measuring the perception of
stress. It is a self-reported, uni-dimensional instrument
developed to measure a perceived stress in a person’s life.
It is a measure of the degree to which situations in one’s
life are appraised as stressful. The scale also includes a
number of direct queries about current levels of experienced
stress. Moreover, the questions are of a general nature
and hence are relatively free of content specific to any
subpopulation group.
The State-Trait Anxiety Inventory (STAI) was initially
conceptualized as a research instrument for the study of
anxiety in adults. It is a self-reported assessment device that
includes separate measures of state and trait anxiety. Accord-
ing to the author of this tool, state anxiety reflects a ‘transitory
emotional state or condition of the human organism that is
characterized by subjective, consciously perceived feelings of
tension and apprehension, and heightened autonomic nervous
system activity’. State anxiety may fluctuate over time and can
vary in intensity. In contrast, trait anxiety denotes ‘relatively
stable individual differences in anxiety proneness...’ and
refers to a general tendency to respond with anxiety to
perceived threats in the environment (30).
The Beck Depression Inventory Second Edition (BDI-II) is a
21-item self-reporting instrument intended to assess the
existence and severity of symptoms of depression as listed
in the American Psychiatric Association’s Diagnostic and
Statistical Manual of Mental Disorders Fourth Edition (DSM-
IV; 1994). This new revised edition replaces the BDI and the
BDI-1A, and includes items intending to index symptoms of
severe depression, which would require hospitalization. Items
have been changed to indicate increases or decreases in
sleep and appetite, items labeled body image, work difficulty,
weight loss and somatic preoccupation were replaced with
items labeled as agitation, concentration difficulty and loss of
energy. Many statements were reworded resulting in a
substantial revision of the original BDI and BDI-1A. When
presented with the BDI-II, a patient is asked to consider each
statement as it relates to the way they have felt for the
past 2 weeks, to more accurately correspond to the DSM-IV
criteria.
Statistical Analyses
Results were analyzed using one-way ANOVA. Scores for
each test as well as the objective samples were independently
assessed and only in the case of the SF-36v2 was the test
divided into physical and psychological summary categories.
Results
We enrolled 18 participants for the 12 week period. Seventeen
participants completed the trial. One participant withdrew
due to scheduling conflicts. Table 1 displays the overall effects
of OCTA  on primary subjective outcomes. Table 2 reports
results from the SF-36v2 Quality of Life results in all eight
domains. Table 3 displays selected objective outcome
measures including serum DHEA levels, urinary creatinine
and levels of the liver enzymes AST and ALT. No significant
changes in blood pressure and cholesterol were observed in
any of the participants (data not shown). None of the
participants reported self-perceived adverse events, nor were
any observed by the monitoring physician.
For our primary outcomes, we observed a 46% improvement
in self-perceived stress. The state and trait anxiety scale
reported overall changes from baseline of 40 and 26%,
respectively. The Beck Depression Index improved by 67%.
For the SF-36 questionnaire, the mental summary score
improved by 72%. Each of these results was statistically
significant with P-values all <0.0001. The physical summary
of the SF-36 demonstrated a modest improvement of 9%;
however, this was not statistically significant (P ¼ 0.228).
ANOVA of serum DHEA demonstrated no change from
baseline (P ¼ 0.98).
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The findings of this trial should be of interest to physicians
and patients alike. We found an overall improvement in
perceptions of stress and quality of life due to changes
associated with stress as monitored by valid stress and quality
of life markers.
Limitations
There are several limitations to consider in our trial. As this
is a pilot trial, we did not use a randomized controlled
design, thus limiting the strength of inference. Additionally,
we cannot determine the extent of any potential changes,
benefit or harm, to internal organs apart from liver and renal
function. It is also quite possible that even though acute
adverse effects were not witnessed over the 3 month trial, a
longer time period of consumption might lead to unforeseen
side effects and possible organ toxicity.
Strengths
Several important strengths to this study deserve mention.
Primarily, this trial is the first to assess this herbal combination
on stress levels in a clinical setting. In addition, we used
well-validated self-reporting tools and tested over an extended
period of time. The participants were monitored for adverse
effects and compliance through oral reporting and the use
of a daily journal. Compliance as indicated by dosing
times recorded in the journal was found to be excellent
(>80%). To establish significance we used cut-offs (P   0.01)
far beyond the standard significance threshold (P   0.05).
Complementary and alternative medicine (CAM) inter-
vention research has often been based on a mind–body
medicine approach with an emphasis on relaxation techniques
like yoga, meditation and modified breathing techniques
(31,32). Another approach in CAM which has not received
as much attention is the use of ingested natural health products
to provide a pharmacological action in order to provide
an ‘adaptogenic’ or protective effect against stress. Our pilot
Table 1. Subjective score summaries of the self-reported questionnaires
Perceived stress
scale
State anxiety
scale
Trait anxiety
scale
Beck depression
scale
SF-36 physical
summary
SF-36 mental
summary
Initial 25.11 53.44 53.33 23.94 46.75 27.57
Week 2 20.29 44.65 50.18 16.65 50.29 34.25
Week 4 18.25 40.69 45.25 12.38 49.10 39.56
Week 8 15.88 35.94 42.82 10.35 51.84 41.78
Week 12 13.53 32.24 39.71 7.82 51.09 47.50
Change 11.58 21.21 13.63 16.12 4.35 19.92
% Change 46.12 39.68 25.55 67.33 9.30 72.25
F-value 10.95 10.67 7.09 9.33 1.44 11.51
P-value <0.0001 <0.0001 <0.0001 <0.0001 0.23 <0.0001
Table 2. SF-36v2 Quality of life results: individual categories
Physical
function
Physical
limitation
Body pain General
health
Vitality Social
function
Emotional
limitation
Mental
health
Initial 47.09 36.99 41.15 41.07 35.09 32.91 28.88 32.64
Week 2 48.86 43.02 46.33 44.94 43.64 38.88 34.16 37.75
Week 4 48.09 43.54 47.56 45.81 45.26 43.56 37.41 42.44
Week 8 51.59 45.90 50.11 49.23 47.50 44.34 40.79 45.37
Week 12 51.71 47.92 49.59 51.28 50.62 47.87 46.96 48.68
Change 4.61 10.93 8.44 10.21 15.53 14.95 18.08 16.04
% Change 9.80 29.56 20.50 24.86 44.25 45.44 62.58 49.14
Table 3. Objective measures including toxicity data
Serum DHEA
(mmol l
 1)
Aspartate
transaminase
(U l
 1)
Alanine
transaminase
(U l
 1)
Urinary
creatinine
(mmol l
 1)
Initial 4.12 21.50 20.50 11.84
Week 2 4.64 23.00 21.56 10.68
Week 4 4.20 22.44 20.79 11.46
Week 8 4.32 22.47 21.12 10.55
Week 12 4.65 21.88 20.24 11.27
Change 0.54 0.38  0.26  0.58
% 13.03 1.78  1.29  4.86
F-value 0.118 0.155 0.087 0.254
P-value 0.97 0.96 0.99 0.91
378 Adaptogenic potential of a polyherbal compoundstudy addresses some of this knowledge gap by assessing
the effects of a combined herbal compound, OCTA ,o n
parameters of stress and its effects on the mental state of the
individual. If the results of our trial are to be trusted and
assumed to not solely be due to placebo, then we can infer that
this polyherbal compound does have a specific effect and
could be an effective aid in controlling at least some of the
negative psychological manifestations of stress.
Stress Physiology and Adaptogenic Effect
Exemplified in the relatively new field of psychoneuroim-
munology, stress invariably leads to a systemic physiological
response with implications for the maintenance of both health
and predisposition towards disease (14,33). The physiology of
stress has been well characterized with an emphasis on the
hypothalamic–pituitary–adrenal axis. Briefly, we know that
the immune system and the nervous system are in constant
communication and are held in a subtle balance that can be
distorted by the impact of stress. Three key players, the
hypothalamus, pituitary gland and adrenal glands are consid-
ered principal effectors in transmitting and amplifying the
stress signal (11). The hypothalamus releases corticotrophin-
releasing hormone (CRH) that then stimulates the adjacent
pituitary gland to secrete adrenocorticotropin hormone
(ACTH). In turn, circulating ACTH stimulates the adrenal
gland to secrete epinephrine, norepinephrine and ultimately
cortisol into the bloodstream resulting in the classic symptoms
of the fight or flight response (Fig. 1). It is important to note
that many cytokines and inflammatory modulators feed into
the stress signal at different physiological points and are also
critical in their contribution to the overall picture.
With such a complex system involved in the body’s
realization of stress, it is plausible that a compound mixture
of herbs could have a modulatory and adaptogenic effect on
the body’s overall response to stress. An analogous repres-
entation of the effects of an adaptogen is depicted in the
change of a system’s tendency towards balance as shown
in Fig. 2. This is represented by a simple fulcrum and balance
beam. When an adaptogen is added to the system,
(i.e. stabilizing damping springs) additional force has to be
applied to deviate the balance beam from the horizontal
thereby making the system less likely to become perturbed to
one side or the other. In this scenario, the adaptogen effectively
counteracts the effective ‘weight’ that a stressor has on the
system and thus makes it less likely to ‘fall’ into the
sympathetic stressed state.
Whether the potential adaptogenic effect of this compound
occurs in the mental state and personal perception of
stress, or through the provision of a more direct physico-
chemical attenuating effect is not answerable by this study.
An examination of the different changes in QOL measures,
however, does have subtle implications. The fact that the
score of mental components of the SF-36 showed dramatic
improvements whereas the physical components score chan-
ged little implies that the effect may be more psychological
than physical. In addition, a possible implication of a lack of
a change in physical symptoms from the SF-36 questionnaire
is that placebo may not actually account for the lion’s share
of the changes in the psychological domain. If placebo
was indeed the principle effector, then changes should have
been noticeable in both the physical and psychological
domains and not just in the latter. These implications are
purely theoretical however and should be tested in more
mechanistic-based research.
Further Research
As well as conducting a controlled trial to eliminate the
placebo effect, it would be interesting to conduct research that
Figure 2. Counteractive adaptogenic effect against stress.
Figure 1. Principal endocrine axis of the sympathetic nervous system.
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including IL-6, TNF and IL-1 as well as examining changes
in lymphocyte and neutrophil counts. The use of antioxidants
has been shown to reduce stress-induced lymphopenia (34) and
it would be optimal to evaluate the impact of the herbs
contained within OCTA  either individually or in combina-
tion on the immune system in further research.
Conclusion
The lack of adverse effects found in our study as well as
an absence of changes in both liver and renal function
tests tentatively supports the notion that this herbal mixture
is non-toxic. Well-controlled and longer-term studies are
needed, however, to establish the long-term effects of
this mixture both with regards to efficacy and toxicity. In
addition, the small number of participants in our pilot study
does not preclude the possibility that serious side effects
might occur. While inconclusive, the results from this study
are encouraging. Albeit uncontrolled, the pilot study indicates
that a polyherbal compound, OCTA , provides a beneficial
adaptogenic effect. The lack of overt and measurable
toxicity in all participants is also encouraging and supports
the need for more research to better evaluate this polyherbal
compound.
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